Literature DB >> 20506315

Rituximab: wanted dead or alive...

Joan T Merrill, Jill P Buyon.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20506315     DOI： 10.1002/art.27544

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN： 0004-3591


× No keyword cloud information.
  5 in total

Review 1.  Targeting B cells for the treatment of SLE: the beginning of the end or the end of the beginning?

Authors:  Ismael Calero; Iñaki Sanz
Journal:  Discov Med       Date:  2010-11       Impact factor: 2.970

2.  An acquired defect in IgG-dependent phagocytosis explains the impairment in antibody-mediated cellular depletion in Lupus.

Authors:  Anupama Ahuja; Lino L Teichmann; Haowei Wang; Robert Dunn; Marilyn R Kehry; Mark J Shlomchik
Journal:  J Immunol       Date:  2011-08-26       Impact factor: 5.422

3.  B-cell targeted therapy in systemic lupus erythematosus: potential of rituximab.

Authors:  E Wiesik-Szewczyk; M Olesinska
Journal:  Biologics       Date:  2012-09-26

4.  An update on belimumab for the treatment of lupus.

Authors:  Aikaterini Thanou-Stavraki; Amr H Sawalha
Journal:  Biologics       Date:  2011-02-14

Review 5.  Mechanisms of B cell autoimmunity in SLE.

Authors:  Thomas Dörner; Claudia Giesecke; Peter E Lipsky
Journal:  Arthritis Res Ther       Date:  2011-10-27       Impact factor: 5.156
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.